CSIMarket Company Name, Ticker, Competitors, else..
 
Urogen Pharma Ltd   (NASDAQ: URGN)
 
Price: $42.8300 $0.52 1.229%
Day's High: $43.71500015258789 Week Perf: -2.25 %
Day's Low: $ 41.65 30 Day Perf: -10.99 %
Volume (M): 256,094 52 Wk High: $ 50.81
Volume (M$): $ 0 52 Wk Avg: $26.93
Open: $42.36 52 Wk Low: $15.86



 Market Capitalization (Millions $) 2,158
 Shares Outstanding (Millions) 50
 Employees 291
 Revenues (TTM) (Millions $) 188
 Net Income (TTM) (Millions $) -98
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) 0

Business Description


Urogen Pharma Ltd is a pharmaceutical company that specializes in the development and commercialization of innovative therapies for urological and urogenital diseases. The company focuses on diseases such as bladder cancer, overactive bladder, and prostate cancer. Urogen Pharma aims to improve the quality of life for patients by providing effective and safe treatments. The company utilizes advanced technologies and research to develop novel drug candidates and therapies, with a focus on precision medicine and targeted therapies. Urogen Pharma is dedicated to addressing unmet medical needs in the urology field and improving patient outcomes.


   Company Address: 400 Alexander Park Drive Princeton 8540 NJ
   Company Phone Number: 768-9780   Stock Exchange / Ticker: NASDAQ URGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -4.2%    
MDGL   -0.63%    
PFE   -2.48%    
RYTM   -0.58%    
SUPN   -2.94%    
ZYME   -8.09%    
• View Complete Report
   



Clinical Study

UroGen Pharma Advances Bladder Cancer Fight with Milestone Phase 3 Trial Enrollment Amid Industry Challenges,

Published Tue, Jul 8 2025 8:39 AM UTC

UroGen Pharma Reaches Major Milestone in Fight Against Non-Muscle Invasive Bladder Cancer PRINCETON, N.J., July 07, 2025 UroGen Pharma Ltd. (Nasdaq: URGN), a pioneering biotech company focused on developing innovative treatments for urothelial and specialty cancers, has announced a significant milestone in its endeavor to revolutionize cancer treatment. The company compl...
Business Update

Groundbreaking Progress in Bladder Cancer Treatment UroGen Pharmas UGN-102 Shines in ENVISION Trial Subgroup...

Published Mon, Feb 17 2025 4:44 PM UTC

In an era where precision medicine is increasingly at the forefront of cancer treatment, UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from the subgroup analyses of its pivotal ENVISION trial. This trial is critical for understanding the effects of UGN-102, an investigational drug aimed at treating patients with low-grade, intermediate-risk non-muscle i...
Business Update

From Trial Triumphs to Market Minefields UroGen Pharma’s Pursuit of Bladder Cancer Breakthroughs Amidst Financial T...

Published Mon, Feb 17 2025 11:38 AM UTC

Navigating the Tumultuous Waters of Biotech: UroGen’s Resilience and Innovation Amidst Market Challenges In the dynamic and rapidly evolving world of biotechnology, the journey from research and development to commercialisation is fraught with challenges and opportunities alike. UroGen Pharma Ltd. a leading player in the realm of urothelial and specialty cancer treatments,...
Business Update

Blazing a New Trail UroGen’s UGN-102 Edges Toward FDA Approval for Bladder Cancer Treatment,

Published Fri, Dec 6 2024 12:47 AM UTC

UGN-102: A Promising New Approach in the Fight Against Bladder Cancer UroGen Pharma Ltd. a pioneering biotech company in the field of urothelial and specialty cancer treatments, has been making significant strides with its investigational therapy UGN-102 (mitomycin), aiming to address a longstanding gap in the treatment landscape. The recent developments concerning UGN-102 h...
Business Update

A New Hope in Bladder Cancer UGN-102 Edges Closer to FDA Approval with Stellar Phase 3 Results,

Published Thu, Dec 5 2024 8:47 PM UTC

Breakthrough in Urothelial Cancer: UGN-102 Shows Potential as First FDA-Approved Treatment for LG-IR-NMIBC In a promising stride for urothelial cancer treatment, UroGen Pharma Ltd. (NASDAQ: URGN) has announced impressive interim results from the Phase 3 ENVISION trial of their investigational therapy, UGN-102. Presented at the Society of Urologic Oncology (SUO) annual meetin...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 11.46
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.74
Working Capital Ratio 3.78
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.99 $
Revenues (TTM) 3.74 $
Cash Flow (TTM) 0.34 $
Cash 2.14 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 647,137
Net Income per Employee (TTM) -335,519
Receivable Turnover Ratio (TTM) 3.82
Inventory Turnover Ratio (TTM) 1.54
Asset Turnover Ratio (TTM) 0.67

Profitability Ratios Current
Gross Margin (MRQ) 90.93 %
Operating Margin (MRQ) 0.15 %
Net Margin (MRQ) -19.81 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Urogen Pharma Ltd's Segments
Jelmyto    60.37 % of total Revenue
Zusduri    109.96 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.